#1973303
ciallaíonn ‘paisinéir atá ionfhabhtaithe’ paisinéir a chomhlíonann an critéar saotharlainne maidir le hionfhabhtú SARS-CoV-2;
‘infected passenger’ means a passenger who fulfils the laboratory criterion for SARS-CoV-2 infection;
Filter results
Collections
251 results in 78 documents
#1973342
athraitheach den víreas SARS-CoV-2;
variant of SARS-CoV-2 virus;
#1979172
Dá réir sin, maidir leis na srianta ar an tsaorghluaiseacht arna gcur i bhfeidhm chun leathadh SARS-CoV-2 a theorannú, i gcás ina nglacfaidh na Ballstáit le cruthúnas ar vacsaíniú, téarnamh ó ionfhabhtú SARS-CoV-2 nó tástáil le haghaidh SARS-CoV-2 ar mhaithe leis na srianta sin a tharscaoileadh, tá na Ballstáit le glacadh freisin, faoi na coinníollacha céanna, le deimhnithe vacsaínithe i ndáil le vacsaín COVID-19 ar tugadh údarú margaíochta ina leith de bhun Rialachán (CE) Uimh. 726/2005, deimhnithe téarnaimh, nó deimhnithe tástála a léiríonn toradh diúltach arna n-eisiúint ag an Eilvéis i gcomhréir le hOrdú na hEilvéise maidir le Deimhnithe COVID-19.
Accordingly, where Member States accept proof of vaccination, of recovery from SARS-CoV-2 infection or of a test for SARS-CoV-2 infection in order to waive restrictions to free movement put in place to limit the spread of SARS-CoV-2, they are also to accept, under the same conditions, vaccination certificates for a COVID-19 vaccine having been granted marketing authorisation pursuant to Regulation (EC) No 726/2004, certificates of recovery, or test certificates indicating a negative result, issued by Switzerland in accordance with the Swiss COVID-19 Certificate Order.
#1992608
"vp": "1119349007" (vacsaín teachtaire NRA SARS-CoV-2)
"vp": "1119349007"(a SARS-CoV-2 mRNA vaccine)
#2043838
Is feiniméan nádúrtha iad sócháin víris SARS-CoV-2 agus féadfar a bheith ag súil go dtarlóidh siad.
Mutations of the SARS-CoV-2 virus are a natural phenomenon and to be expected.
#2074131
Chun an dul chun cinn eolaíoch maidir le paindéim COVID-19 a choinneáil faoi smacht a chur san áireamh, nó chun idir-inoibritheacht le caighdeáin idirnáisiúnta a áirithiú, ba cheart an chumhacht chun gníomhartha a ghlacadh i gcomhréir le hAirteagal 290 CFAE a tharmligean chuig an gCoimisiún chun an Rialachán seo a leasú trí na réimsí sonraí a mhodhnú nó a bhaint, ar réimsí sonraí iad a bheidh le háireamh i nDeimhniú Digiteach COVID AE maidir le céannacht an tsealbhóra, faisnéis faoi vacsaín in aghaidh COVID-19, faoin tástáil le haghaidh ionfhabhtú SARS-CoV-2, faoi ionfhabhtú SARS-CoV-2 a tharla roimhe seo agus faoi mheiteashonraí an deimhnithe, trí réimsí sonraí maidir le céannacht an tsealbhóra, faisnéis faoi vacsaín in aghaidh COVID-19, faoin tástáil le haghaidh ionfhabhtú SARS-CoV-2, faoi ionfhabhtú SARS-CoV-2 a tharla roimhe seo agus faoi mheiteashonraí an deimhnithe a chur leis agus trí leasú a dhéanamh ar an líon laethanta ar ina dhiaidh atá deimhniú téarnaimh le heisiúint.
In order to take into account the scientific progress in containing the COVID-19 pandemic, or to ensure interoperability with international standards, the power to adopt acts in accordance with Article 290 TFEU should be delegated to the Commission to amend this Regulation by modifying or removing the data fields to be included in the EU Digital COVID Certificate regarding the identity of the holder, information about the COVID-19 vaccine, the test for SARS-CoV-2 infection, past SARS-CoV-2 infection and the certificate metadata, by adding data fields regarding information about the COVID-19 vaccine, the test for SARS-CoV-2 infection, past SARS-CoV-2 infection and certificate metadata and by amending the number of days after which a certificate of recovery is to be issued.
#2074234
faisnéis faoi ionfhabhtú SARS-CoV-2 a tharla roimhe seo i ndiaidh toradh tástála dearfaí;
information about past SARS-CoV-2 infection of the holder following a positive test result;
#2074364
an galar nó an t-oibreán ar ar díríodh: COVID-19 (SARS-CoV-2 nó ceann dá chuid athraitheach);
disease or agent targeted: COVID-19 (SARS-CoV-2 or one of its variants);
#2438322
Mar sin féin, tá an víreas SARS-CoV-2 fós ag scaipeadh leis.
However, the SARS-CoV-2 virus is still circulating.
#2637492
Tá leanaí de gach aois so-ghabhálach i leith SARS-CoV-2 agus is féidir leo é a tharchur.
Children of all ages are susceptible to and can transmit SARS-CoV-2.
#1973320
Maidir le sonraí pearsanta a phróiseáil in ardán malartaithe PLF chun críche rianaithe teagmhálaithe SARS-CoV-2 agus chun na críche sin amháin, déanfar na sonraí sin a phróiseáil go dtí an 31 Bealtaine 2022 nó dtí go mbeidh sé dearbhaithe ag Ard-Stiúrthóir na hEagraíochta Domhanda Sláinte, i gcomhréir leis na Rialacháin Sláinte Idirnáisiúnta, go bhfuil deireadh tagtha leis an éigeandáil sláinte poiblí arb ábhar imní ar leibhéal idirnáisiúnta í, éigeandáil atá mar thoradh ar SARS-CoV-2, cibé acu is luaithe.
Processing of personal data in the PLF exchange platform for the sole purpose of SARS-CoV-2 contact tracing shall be performed until 31 May 2022 or until the Director-General of the World Health Organization has declared, in accordance with the International Health Regulations, that the public health emergency of international concern caused by SARS-CoV-2 has ended, whichever is the earliest.
#1977104
Is sampla iad seo a leanas de chóid ar cheart a úsáid ó na córais cód roghnaithe: cód SNOMED CT 1119305005 (vacsaín antaigine SARS-CoV-2), 1119349007 (vacsaín teachtaire RNA SARS-CoV-2) nó J07BX03 (vacsaíní COVID-19).
Examples of codes that should be used from the preferred code systems are the SNOMED CT code 1119305005 (SARS-CoV-2 antigen vaccine), 1119349007 (SARS-CoV-2 mRNA vaccine) or J07BX03 (covid-19 vaccines).
#1979167
Maidir leis na srianta ar an tsaorghluaiseacht arna gcur i bhfeidhm, i gcomhréir le FMOPA, agus staid shonrach na bpobal trasteorann á cur san áireamh, chun leathadh SARS-CoV-2 a theorannú, chuir an Eilvéis in iúl don Choimisiún freisin gur i gcás ina n-éileoidh an Eilvéis cruthúnas ar thástáil ar ionfhabhtú SARS-CoV-2 ar mhaithe leis na srianta sin a tharscaoileadh, go nglacfaidh sí freisin, faoi na coinníollacha céanna, le deimhnithe tástála a léiríonn toradh diúltach arna n-eisiúint ag na Ballstáit i gcomhréir leis an Rialachán seo.
Switzerland further informed the Commission that where Switzerland requires proof of a test for SARS-CoV-2 infection in order to waive the restrictions to free movement put in place, in accordance with the FMOPA, and taking into account the specific situation of cross-border communities, to limit the spread of SARS-CoV-2, it will also accept, under the same conditions, test certificates indicating a negative result issued by Member States in accordance with Regulation (EU) 2021/953.
#1979168
Ina theannta sin, maidir leis na srianta ar an tsaorghluaiseacht arna gcur i bhfeidhm, i gcomhréir le FMOPA, chun leathadh SARS-CoV-2 a theorannú, chuir an Eilvéis in iúl don Choimisiún gur i gcás ina nglacfaidh sí le cruthúnas ar théarnamh ó ionfhabhtú SARS-CoV-2 ar mhaithe leis na srianta sin a tharscaoileadh, go nglacfaidh sí freisin, faoi na coinníollacha céanna, le deimhnithe téarnaimh arna n-eisiúint ag na Ballstáit i gcomhréir le Rialachán (AE) 2021/953.
Switzerland also informed the Commission that where Switzerland accepts proof of recovery from SARS-CoV-2 infection in order to waive restrictions to free movement put in place, in accordance with the FMOPA, to limit the spread of SARS-CoV-2, it will accept, under the same conditions, certificates of recovery issued by Member States in accordance with Regulation (EU) 2021/953.
#1992443
Is sampla iad seo a leanas de chóid a úsáidfear ó na córais cód roghnaithe: cód SNOMED CT 1119305005 (vacsaín antaigine SARS-CoV-2), 1119349007 (vacsaín teachtaire RNA SARS-CoV-2) nó J07BX03 (vacsaíní COVID-19).
Examples of codes that shall be used from the preferred code systems are the SNOMED CT code 1119305005 (SARS-CoV-2 antigen vaccine), 1119349007 (SARS-CoV-2 mRNA vaccine) or J07BX03 (covid-19 vaccines).
#2073953
Chun leathadh SARS-CoV-2 a theorannú, tá roinnt beart glactha ag na Ballstáit, bearta a raibh tionchar acu ar shaoránaigh den Aontas agus a gceart á fheidhmiú acu gluaiseacht agus cónaí faoi shaoirse ar chríoch na mBallstát, amhail srianta ar dhul isteach nó ceanglais ar thaistealaithe trasteorann coraintín nó féinleithlisiú nó tástáil le haghaidh ionfhabhtú SARS-CoV-2 a dhéanamh.
To limit the spread of SARS-CoV-2, the Member States have adopted some measures which have had an impact on the exercise by Union citizens of their right to move and reside freely within the territory of the Member States, such as entry restrictions or requirements for cross-border travellers to undergo quarantine or self-isolation or to be tested for SARS-CoV-2 infection.
#2073954
An 13 Deireadh Fómhair 2020, ghlac an Chomhairle Moladh (AE) 2020/1475, lenar tugadh isteach cur chuige comhordaithe i leith an tsaorghluaiseacht a shrianadh mar fhreagairt ar phaindéim COVID-19 sna príomhréimsí seo a leanas: critéir chomhchoiteanna agus tairseacha comhchoiteanna a chur i bhfeidhm, agus cinneadh á dhéanamh ar cheart srianta ar an tsaorghluaiseacht a thabhairt isteach, mapáil ar limistéir riosca thras-seoladh SARS-CoV-2 bunaithe ar chód dathanna comhaontaithe agus cur chuige comhordaithe i leith aon bhearta iomchuí a d’fhéadfaí a chur i bhfeidhm maidir le daoine atá ag taisteal go dtí limistéir riosca nó uathu, ag brath ar leibhéal an riosca a bhaineann le tras-seoladh SARS-CoV-2 sna limistéir sin.
On 13 October 2020, the Council adopted Recommendation (EU) 2020/1475, which introduced a coordinated approach to the restriction of free movement in response to the COVID-19 pandemic in the following key areas: the application of common criteria and thresholds when deciding whether to introduce restrictions to free movement, a mapping of risk areas of SARS-CoV-2 transmission based on an agreed colour code and a coordinated approach to any appropriate measures which could be applied to persons travelling to or from risk areas, depending on the level of risk of SARS-CoV-2 transmission in those areas.
#2074049
I gcás ina nglacfaidh Ballstáit le cruthúnas ar vacsaíniú chun srianta ar an tsaorghluaiseacht a cuireadh i bhfeidhm, i gcomhréir le dlí an Aontais chun teorainn a chur le leathadh SARS-CoV-2, a tharscaoileadh, amhail ceanglas chun coraintín nó féinleithlisiú nó tástáil le haghaidh ionfhabhtú SARS-CoV-2 a dhéanamh, ba cheart a cheangal orthu glacadh le deimhnithe vacsaínithe arna n-eisiúint ag Ballstáit eile i gcomhréir leis an Rialachán seo faoi na coinníollacha céanna.
Where Member States accept proof of vaccination in order to waive restrictions to free movement put in place, in accordance with Union law to limit the spread of SARS-CoV-2, such as a requirement to undergo quarantine or self-isolation or to be tested for SARS-CoV-2 infection, they should be required to accept, under the same conditions, vaccination certificates issued by other Member States in accordance with this Regulation.
#2074086
Ballstáit a éilíonn cruthúnas ar thástáil le haghaidh ionfhabhtú SARS-CoV-2 chun na srianta ar an tsaorghluaiseacht a cuireadh i bhfeidhm chun teorainn a chur le leathadh SARS-CoV-2 a tharscaoileadh, ba cheart do na Ballstáit sin glacadh le deimhnithe tástála COVID-19 lena léirítear toradh diúltach arna n-eisiúint ag na Ballstáit i gcomhréir leis an Rialachán seo faoi na coinníollacha céanna.
COVID-19 test certificates indicating a negative result issued by Member States in accordance with this Regulation should be accepted, under the same conditions, by Member States requiring proof of a test for SARS-CoV-2 infection in order to waive the restrictions to free movement put in place to limit the spread of SARS-CoV-2.
#2074092
De réir ECDC, tá sé léirithe le fianaise a cuireadh ar fáil le déanaí, cé gur féidir SARS-CoV-2 inmharthana a scoitheadh idir 10 agus 20 lá tar éis thús na siomptóm, gur mhainnigh staidéir eipidéimeolaíochta a léiriú go cinntitheach gur féidir SARS-CoV-2 a thras-sheoladh ar aghaidh tar éis 10 lá.
According to the ECDC, recent evidence shows that despite shedding of viable SARS-CoV-2 between ten and twenty days from the onset of symptoms, convincing epidemiological studies have failed to show onward SARS-CoV-2 transmission after ten days.
#2074095
I gcás ina nglacfaidh Ballstáit le cruthúnas ar théarnamh chun srianta ar an tsaorghluaiseacht a cuireadh i bhfeidhm, i gcomhréir le dlí an Aontais, chun teorainn a chur le leathadh SARS-CoV-2 a tharscaoileadh, amhail ceanglais chun coraintín nó féinleithlisiú nó tástáil le haghaidh ionfhabhtú SARS-CoV-2 a dhéanamh, ba cheart a cheangal orthu glacadh, faoi na coinníollacha céanna, le deimhnithe téarnaimh ó COVID-19 arna n-eisiúint ag Ballstáit eile i gcomhréir leis an Rialachán seo.
Where Member States accept proof of recovery in order to waive restrictions to free movement put in place, in accordance with Union law, to limit the spread of SARS-CoV-2, such as a requirement to undergo quarantine or self-isolation or to be tested for SARS-CoV-2 infection, they should be required to accept, under the same conditions, certificates of recovery from COVID-19 issued by other Member States in accordance with this Regulation.
#2074098
Chun go mbeidh sé ar chumas an Choimisiúin teacht ar chomhsheasamh go mear, ba cheart dó a bheith in ann a iarraidh ar an gCoiste Slándála Sláinte, ar ECDC nó ar EMA treoir a eisiúint maidir leis an bhfianaise eolaíoch atá ar fáil maidir le hiarmhairtí teagmhas leighis a dhoiciméadaítear i ndeimhnithe arna mbunú i gcomhréir leis an Rialachán seo, lena n-áirítear éifeachtacht agus fad thréimhse na himdhíonachta arna tabhairt le vacsaíní in aghaidh COVID-19, cibé acu a chuireann nó nach gcuireann vacsaíní cosc ar ionfhabhtú aisiomptómach agus tras-seoladh SARS-CoV-2, staid na ndaoine atá téarnaithe ó COVID-19, agus an tionchar atá ag athraithigh SARS-CoV-2 nua ar dhaoine atá vacsaínithe nó ionfhabhtaithe cheana.
To be able to obtain a common position quickly, the Commission should be able to ask the Health Security Committee, the ECDC or EMA to issue guidance on the available scientific evidence on the effects of medical events documented in the certificates established in accordance with this Regulation, including the effectiveness and duration of the immunity conferred by COVID-19 vaccines, whether vaccines prevent asymptomatic infection and SARS-CoV-2 transmission, the situation of people having recovered from COVID-19, and the impacts of the new SARS-CoV-2 variants on people who have been vaccinated or already infected.
#2074159
ciallaíonn “tástáil antasubstainte” tástáil saotharlainn-bhunaithe arb é is aidhm léi a bhrath an bhfuil antasubstaintí i gcoinne SARS-CoV-2 forbartha ag duine, rud a léiríonn gur nochtadh an sealbhóir do SARS-CoV-2 agus gur fhorbair sé nó sí antasubstaintí, is cuma cé acu an raibh siomptóim ag an duine sin nó nach raibh;
‘antibody test’ means a laboratory-based test aiming to detect if a person has developed antibodies against SARS-CoV-2, thus indicating that the holder has been exposed to SARS-CoV-2 and has developed antibodies, regardless of whether that person was symptomatic;
#2074227
Srianta ar an tsaorghluaiseacht arna gcur i bhfeidhm, i gcomhréir le dlí an Aontais agus staid shonrach na bpobal trasteorann á cur san áireamh, chun leathadh COVID-19 a theorannú, i gcás ina n-éileoidh na Ballstáit cruthúnas ar thástáil le haghaidh ionfhabhtú SARS-CoV-2 chun na srianta sin a tharscaoileadh, glacfaidh siad freisin, faoi na coinníollacha céanna, le deimhnithe tástála lena léirítear toradh diúltach arna n-eisiúint ag Ballstáit eile i gcomhréir leis an Rialachán seo.
Where Member States require proof of a test for SARS-CoV-2 infection in order to waive the restrictions to free movement put in place, in accordance with Union law and taking into account the specific situation of cross-border communities, to limit the spread of SARS-CoV-2, they shall also accept, under the same conditions, test certificates indicating a negative result issued by other Member States in accordance with this Regulation.
#2074243
Srianta ar an tsaorghluaiseacht arna gcur i bhfeidhm, i gcomhréir le dlí an Aontais, chun leathadh COVID-19 a theorannú, i gcás ina nglacfaidh na Ballstáit le cruthúnas téarnaimh ó ionfhabhtú SARS-CoV-2 chun na srianta sin a tharscaoileadh, glacfaidh siad, faoi na coinníollacha céanna, le deimhnithe téarnaimh arna n-eisiúint ag Ballstáit eile i gcomhréir leis an Rialachán seo.
Where Member States accept proof of recovery from SARS-CoV-2 infection in order to waive restrictions to free movement put in place, in accordance with Union law, to limit the spread of SARS-CoV-2, they shall accept, under the same conditions, certificates of recovery issued by other Member States in accordance with this Regulation.
#2074286
I gcás ina gceanglóidh Ballstát, i gcomhréir le dlí an Aontais, ar shealbhóirí na ndeimhnithe dá dtagraítear in Airteagal 3 tabhairt faoi choraintín, féinleithlisiú nó tástáil le haghaidh ionfhabhtú SARS-CoV-2 tar éis dóibh dul isteach ina chríoch, nó i gcás ina bhforchuireann sé srianta eile ar shealbhóirí deimhnithe den sórt sin toisc, mar shampla, go dtéann an staid eipidéimeolaíoch i mBallstát nó i réigiún laistigh de Bhallstát in olcas go tapa, go háirithe mar thoradh ar athraitheach SARS-CoV-2 is ábhar imní nó suime, cuirfidh sé an Coimisiún agus na Ballstáit eile ar an eolas dá réir sin, 48 n-uair an chloig sula dtabharfar srianta nua den sort sin isteach, más féidir.
Where a Member State requires, in accordance with Union law, holders of the certificates referred to in Article 3(1) to undergo, after entry into its territory, quarantine or self-isolation or to be tested for SARS-CoV-2 infection, or if it imposes other restrictions on the holders of such certificates because, for example, the epidemiological situation in a Member State or in a region within a Member State worsens quickly, in particular as a result of a SARS-CoV-2 variant of concern or interest, it shall inform the Commission and the other Member States accordingly, if possible 48 hours in advance of the introduction of such new restrictions.
#2074402
Chun leathadh SARS-CoV-2 a theorannú, tá roinnt beart glactha ag na Ballstáit, bearta a raibh tionchar ag roinnt acu ar thaisteal chuig agus laistigh de chríoch na mBallstát, amhail srianta ar dhul isteach nó ceanglais ar thaistealaithe trasteorann coraintín nó féinleithlisiú nó tástáil le haghaidh ionfhabhtú SARS-CoV-2 a dhéanamh.
To limit the spread of SARS-CoV-2, the Member States have adopted some measures which have had an impact on travel to and within the territory of the Member States, such as entry restrictions or requirements for cross-border travellers to undergo quarantine or self-isolation or to be tested for SARS-CoV-2 infection.
#2074410
I gcás ina nglacfaidh Ballstáit le cruthúnas ar vacsaíniú chun srianta taistil a cuireadh i bhfeidhm a tharscaoileadh, i gcomhréir le dlí an Aontais, chun teorainn a chur le leathadh SARS-CoV-2, amhail ceanglas chun coraintín, féinleithlisiú nó tástáil le haghaidh ionfhabhtú SARS-CoV-2 a dhéanamh, ba cheart a cheangal orthu, faoi na coinníollacha céanna, glacadh le deimhnithe vacsaínithe arna n-eisiúint ag Ballstáit eile i gcomhréir le Rialachán (AE) 2021/953 ó Pharlaimint na hEorpa agus ón gComhairle.
Where Member States accept proof of vaccination in order to waive travel restrictions put in place, in accordance with Union law to limit the spread of SARS-CoV-2, such as a requirement to undergo quarantine or self-isolation or to be tested for SARS- CoV-2 infection, they should be required to accept, under the same conditions, vaccination certificates issued by other Member States in accordance with Regulation (EU) 2021/953. of the European Parliament and of the Council.
#2265816
Léiríodh leis na hathraithigh ‘Alpha’, ‘Delta’ agus ‘Omicron’ SARS-CoV-2, arb é an tríú ceann an t-athraitheach is coitianta anois san Aontas, an drochthionchar is féidir a bheith ag athraithigh nua SARS-CoV-2 ar an staid eipidéimeolaíoch.
The SARS-CoV-2 variants ‘Alpha’, ‘Delta’ and ‘Omicron’, the latter in the process of becoming the dominant variant within the Union, have demonstrated the negative impact new SARS-CoV-2 variants can have on the epidemiological situation.
#2265819
Mar a leagtar amach i Rialachán (AE) 2021/953, i gcás ina gcuirfidh Ballstát, i gcomhréir le dlí an Aontais, de cheangal ar shealbhóirí Dheimhniú Digiteach COVID AE coraintín a dhéanamh nó féinleithlisiú nó tástáil le haghaidh ionfhabhtú SARS-CoV-2 a dhéanamh tar éis dóibh dul isteach ina chríoch, nó i gcás ina bhforchuirfidh sé srianta eile ar shealbhóirí na ndeimhnithe sin toisc, mar shampla, go dtéann an staid eipidéimeolaíoch i mBallstát nó i réigiún laistigh de Bhallstát in olcas go tapa, go háirithe mar thoradh ar athraitheach SARS-CoV-2 ar díol imní nó spéise é, cuirfidh sé an Coimisiún agus na Ballstáit eile ar an eolas dá réir sin, 48 uair an chloig sula dtabharfar na srianta nua sin isteach, más féidir.
As set out in Regulation (EU) 2021/953, where a Member State requires, in accordance with Union law, holders of the EU Digital COVID Certificate to undergo, after entry into its territory, quarantine or self-isolation or to be tested for SARS-CoV-2 infection, or if it imposes other restrictions on the holders of such certificates because, for example, the epidemiological situation in a Member State or in a region within a Member State worsens quickly, in particular as a result of a SARS-CoV-2 variant of concern or interest, it is to inform the Commission and the other Member States accordingly, if possible 48 hours in advance of the introduction of such new restrictions.
#2265916
I gcás ina gceanglóidh Ballstát ar thaistealaithe, lena n-áirítear sealbhóirí Deimhnithe Digiteacha COVID AE, coraintín a dhéanamh/féinleithlisiú nó tástáil le haghaidh ionfhabhtú SARS-CoV-2 a dhéanamh tar éis dóibh teacht isteach ina chríoch, nó i gcás ina bhforchuireann sé srianta eile ar shealbhóirí deimhnithe den sórt sin, mar fhreagairt ar theacht chun cinn athraitheach nua SARS-CoV-2 ar díol imní nó spéise é, ba cheart dó an Coimisiún agus na Ballstáit eile a chur ar an eolas dá réir sin, lena n-áirítear tríd an bhfaisnéis dá dtagraítear in Airteagal 11(2) de Rialachán (AE) 2021/953 a chur ar fáil.
Where a Member State requires travellers, including holders of EU Digital COVID Certificates, to undergo, after entry into its territory, quarantine/self-isolation or to be tested for SARS-CoV-2 infection, or if it imposes other restrictions on the holders of such certificates, in response to the emergence of a new SARS-CoV-2 variant of concern or interest, it should inform the Commission and the other Member States accordingly, including by providing the information referred to in Article 11(2) of Regulation (EU) 2021/953.
#2265926
Bunaithe ar mheasúnú rialta ar fhianaise nua ag an Lárionad Eorpach um Ghalair a Chosc agus a Rialú, agus, a luaithe a bheidh sé ar fáil, féadfaidh an Coimisiún an creat a d’fhorbair an Sainghrúpa Eorpach maidir le hathraithigh SARS-CoV-2, plé sa Chomhairle a mholadh freisin maidir le hathraitheach nua SARS-CoV-2 ar díol imní nó spéise é nó maidir le staid eipidéimeolaíoch atá ag dul in olcas go tapa i mBallstát nó i réigiún laistigh de Bhallstát.
The Commission, based on the regular assessment of new evidence on variants by the European Centre for Disease Prevention and Control, and, once available, the framework developed by the European expert group on SARS-CoV-2 variants, may also suggest a discussion within the Council on a new SARS-CoV-2 variant of concern or interest or on a rapidly deteriorating epidemiological situation in a Member State or in a region within a Member State.
#2305981
I gcomhréir le hAirteagal 7(8) de Rialachán (AE) 2021/953, srianta ar an tsaorghluaiseacht arna gcur i bhfeidhm i gcomhréir le dlí an Aontais chun leathadh SARS-CoV-2 a theorannú, i gcás ina nglacfaidh na Ballstáit le cruthúnas téarnaimh ó ionfhabhtú SARS-CoV-2 chun na srianta sin a tharscaoileadh, is gá dóibh glacadh, faoi na coinníollacha céanna, le deimhnithe téarnaimh arna n-eisiúint ag na Ballstáit eile.
In accordance with Article 7(8) of Regulation (EU) 2021/953, where Member States accept proof of recovery from SARS-CoV-2 infection in order to waive restrictions to free movement put in place, in accordance with Union law, to limit the spread of SARS-CoV-2, they are required to accept, under the same conditions, certificates of recovery issued by other Member States.
#2438192
Chun faisnéis thráthúil, ábhartha agus ionadaíoch a fháil maidir le teacht chun cinn agus scaipeadh athraitheacha SARS-CoV-2 ar díol imní nó spéise iad, ba cheart do na Ballstáit measúnú a dhéanamh ar scaipeadh athraitheach éagsúil SARS-CoV-2 sa phobal trí shamplaí ionadaíocha a roghnú lena seicheamhú, trí thréithriú géiniteach a dhéanamh agus torthaí tíopála athraitheacha a thuairisciú i gcomhréir leis an treoraíocht seicheamhaithe arna foilsiú ag an Lárionad Eorpach um Ghalair a Chosc agus a Rialú.
To obtain timely, relevant and representative information on the emergence and circulation of SARS-CoV-2 variants of concern or interest, Member States should assess the circulation of different SARS-CoV-2 variants in the community by selecting representative samples for sequencing, carry out genetic characterisation and report variant typing results in line with the sequencing guidance published by the European Centre for Disease Prevention and Control.
#2438268
I gcás ina gcuirfidh Ballstát de cheangal ar thaistealaithe, lena n-áirítear sealbhóirí Dheimhnithe Digiteacha COVID AE, mar fhreagairt ar athraitheach nua SARS-CoV-2 a theacht chun cinn ar díol imní nó spéise é, coraintín nó féinleithlisiú a dhéanamh nó tástáil a dhéanamh le haghaidh ionfhabhtú SARS-CoV-2 tar éis dóibh teacht isteach ina chríoch, nó má fhorchuireann sé srianta eile ar shealbhóirí deimhnithe mar sin, ba cheart dó an Coimisiún agus na Ballstáit eile a chur ar an eolas go pras dá réir sin, tríd an líonra IPCR, lena n-áirítear tríd an bhfaisnéis dá dtagraítear i bpointe 11c den Mholadh seo, agus in Airteagal 11(2) de Rialachán (AE) 2021/953 a sholáthar.
Where, in response to the emergence of a new SARS-CoV-2 variant of concern or interest, a Member State requires travellers, including holders of EU Digital COVID Certificates, to undergo, after entry into its territory, quarantine or self-isolation or to be tested for SARS-CoV-2 infection, or if it imposes other restrictions on the holders of such certificates, it should, through the IPCR network, swiftly inform the Commission and the other Member States accordingly, including by providing the information referred to in point 11c of this Recommendation, and Article 11(2) of Regulation (EU) 2021/953.
#2438280
Bunaithe ar mheasúnú rialta ar fhianaise nua faoi athraithigh a rinne an Lárionad Eorpach um Ghalair a Chosc agus a Rialú, plé ábhartha maidir leis an tsláinte phoiblí ag an gCoiste Slándála Sláinte agus an anailís a thug an Sainghrúpa Eorpach maidir le hathraithigh SARS-CoV-2, féadfaidh an Coimisiún a mholadh freisin go ndéanfaí plé sa Chomhairle maidir le hathraitheach nua SARS-CoV-2 ar díol imní nó spéise é.”;
The Commission, based on the regular assessment of new evidence on variants by the European Centre for Disease Prevention and Control, relevant public health discussions in the Health Security Committee and the analysis provided by the European expert group on SARS-CoV-2 variants, may also suggest a discussion within the Council on a new SARS-CoV-2 variant of concern or interest.’;
#1969097
Aontaíonn an Coimisiún go bhfuil vacsaíní agus tástálacha COVID-19 d’ionfhabhtú SARS-CoV-2 atá inacmhainne agus inrochtana ríthábhachtach sa chomhrac i gcoinne phaindéim COVID-19.
The Commission agrees that affordable and accessible COVID-19 vaccines and tests for SARS-CoV-2 infection are crucial in the fight against the COVID-19 pandemic.
#1969103
Aontaíonn an Coimisiún go bhfuil vacsaíní agus tástálacha COVID-19 d’ionfhabhtú SARS-CoV-2 atá inacmhainne agus inrochtana ríthábhachtach sa chomhrac i gcoinne phaindéim COVID-19.
The Commission agrees that affordable and accessible COVID-19 vaccines and tests for SARS-CoV-2 infection are crucial in the fight against the COVID-19 pandemic.
#1973316
Ní cheadóidh sé ach d’údaráis inniúla EWRS sonraí a fháil, sonraí a chuir údaráis inniúla eile de chuid EWRS chucu chun críche rianaithe teagmhálaithe SARS-CoV-2 agus chun na críche sin amháin.
It shall only allow EWRS competent authorities to receive data that were sent to them by other EWRS competent authorities for the sole purpose of SARS-CoV-2 contact tracing.
#1977096
An galar nó an toibreán ar ar díríodh/An galar nó an toibreán ónar théarnaigh an sealbhóir: COVID-19 (SARS-CoV-2 nó ceann dá chuid athraitheach)
Disease or agent targeted/Disease or agent from which the holder has recovered: COVID-19 (SARS-CoV-2 or one of its variants)
#1984020
Thairis sin, chuir Monacó in iúl don Choimisiún gur le haghaidh tástálacha SARS-CoV-2 trí imoibriú slabhrúil polaiméaráise cúl-trascrioptáise (RT-PCR), agus lena n-aghaidh sin amháin, a eiseoidh sé deimhnithe tástála idir-inoibritheacha.
Furthermore, Monaco informed the Commission that it will issue interoperable test certificates only for SARS-CoV-2 tests by reverse transcription polymerase chain reaction (RT-PCR).
#1985197
Sa tréimhse roimh phaindéim SARS-CoV-2, reáchtáladh an cruinniú tionscanta (Caireo, Meitheamh 2019) agus an chéad cheardlann fhoréigiúnach (Abú Daibí, Feabhra 2020) de chuid an tionscadail.
In the period preceding the SARS-CoV-2 pandemic, the project held its inception meeting (Cairo, June 2019) and first subregional workshop (Abu Dhabi, February 2020).
#1992431
An galar nó an t-oibreán ar ar díríodh/An galar nó an t-oibreán ónar théarnaigh an sealbhóir: COVID-19 (SARS-CoV-2 nó ceann dá chuid athraitheach)
Disease or agent targeted/Disease or agent from which the holder has recovered: COVID-19 (SARS-CoV-2 or one of its variants)
#1992683
An galar nó an t-oibreán ónar théarnaigh an sealbhóir: COVID-19 (SARS-CoV-2 nó ceann dá chuid athraitheach)
Disease or agent from which the holder has recovered: COVID-19 (SARS-CoV-2 or one of its variants)
#2043831
Is galar tógálach é galar coróinvíris (COVID-19) arb é coróinvíreas nua-aimsithe (SARS-CoV-2) is cúis leis.
Coronavirus disease (COVID-19) is an infectious disease caused by a newly discovered coronavirus (SARS-CoV-2).
#2074066
Tá roinnt mhaith Ballstát ag éileamh ar dhaoine atá ag taisteal go dtí a gcríoch tástáil le haghaidh ionfhabhtú SARS-CoV-2 a dhéanamh sula dtagann siad nó ina dhiaidh sin.
Many Member States have been requiring persons travelling to their territory to undergo a test for SARS-CoV-2 infection before or after arrival.
#2074156
ciallaíonn “vacsaín in aghaidh COVID-19” táirge íocshláinte imdhíoneolaíoch atá léirithe le haghaidh imdhíonadh gníomhach chun COVID-19 arb é SARS-CoV-2 is cúis leis a chosc;
‘COVID-19 vaccine’ means an immunological medicinal product indicated for active immunisation to prevent COVID-19 caused by SARS-CoV-2;
#2074382
an galar nó an t-oibreán ónar théarnaigh an sealbhóir: COVID-19 (SARS-CoV-2 nó ceann dá chuid athraitheach);
disease or agent from which the holder has recovered: COVID-19 (SARS-CoV-2 or one of its variants);
#2245560
lena leasaítear Cinneadh Cur Chun Feidhme (AE) 2021/788 lena leagtar síos rialacha maidir le faireachán agus tuairisciú a dhéanamh ar ionfhabhtuithe SARS-CoV-2 i speicis áirithe ainmhithe
amending Implementing Decision (EU) 2021/788 laying down rules for the monitoring and reporting of infections with SARS-CoV-2 in certain animal species
#2245568
Dá bhrí sin, le Cinneadh Cur Chun Feidhme (AE) 2021/788 an 12 Bealtaine 2021 leagtar síos rialacha maidir le faireachán agus tuairisciú comhchuibhithe a dhéanamh, laistigh den Aontas, ar ionfhabhtuithe SARS-CoV-2 i speicis áirithe ainmhithe.
Commission Implementing Decision (EU) 2021/788 of 12 May 2021 thus lays down rules for harmonised monitoring and reporting, within the Union, of infections with SARS-CoV-2 in certain animal species.